SEARCH

SEARCH BY CITATION

LITERATURE CITED

  • 1
    Brandenberger R, Burgur S, Campbell A, Fong T, Lapinskas E, Rowley JA. Cell therapy bioprocessing integrating process and product development for the next generation of biotherapeutics. Bioprocess Int 2011; 9: 3037.
  • 2
    Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, Levy D, Kubi A, Hovav E, Chermoshniuk N, Shalmon B, Hardan I, Catane R, Markel G, Apter S, Ben-Nun A, Kuchuk I, Shimoni A, Nagler A, Schachter J. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 2010; 16: 26462655.
  • 3
    Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 2003; 26: 332342.
  • 4
    Dudley ME, Wunderlich JR, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry RM, Marincola FM, Leitman SF, Seipp CA, Rogers-Freezer L, Morton KE, Nahvi A, Mavroukakis SA, White DE, Rosenberg SA. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 2002; 25: 243251.
  • 5
    Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA. Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26: 52335239.
  • 6
    Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23: 23462357.
  • 7
    Guidance for FDA Reviews and Sponsors Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs) United States Department of Health and Human Services FaDA. 2008.
  • 8
    Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, Phan GQ, Kammula US, Hughes MS, Citrin DE, Restifo NP, Wunderlich JR, Prieto PA, Hong JJ, Langan RC, Zlott DA, Morton KE, White DE, Laurencot CM, Rosenberg SA. CD8+ enriched “young” tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res 2010; 16: 61226131.
  • 9
    Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, Robbins PF. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol 2005; 175: 70467052.
  • 10
    Huang J, Khong HT, Dudley ME, El-Gamil M, Li YF, Rosenberg SA, Robbins PF. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother 2005; 28: 258267.
  • 11
    Diederichsen AC, Hansen TP, Nielsen O, Fenger C, Jensenius JC, Christensen PB, Kristensen T, Zeuthen J. A comparison of flow cytometry and immunohistochemistry in human colorectal cancers. APMIS 1998; 106: 562570.
  • 12
    Iorgulescu DG, Kiroff GK. Minimal residual marrow disease: Detection and significance of isolated tumour cells in bone marrow. ANZ J Surg 2001; 71: 365376.
  • 13
    Moss TJ. Clinical relevance of minimal residual cancer in patients with solid malignancies. Cancer Metastasis Rev 1999; 18: 91100.
  • 14
    Donnenberg AD, Donnenberg VS. Rare-event analysis in flow cytometry. Clin Lab Med 2007; 27: 627652,viii.
  • 15
    Barrow C, Browning J, Macgregor D, Davis ID, Sturrock S, Jungbluth AA, Cebon J. Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res 2006; 12: 764771.
  • 16
    Hu Y, Fan L, Zheng J, Cui R, Liu W, He Y, Li X, Huang S. Detection of circulating tumor cells in breast cancer patients utilizing multiparameter flow cytometry and assessment of the prognosis of patients in different CTCs levels. Cytometry A 2010; 77A: 213219.
  • 17
    Maecker H, Trotter J. Selecting reagents for multicolor flow cytometry with BDTM LSR II and BD FACSCantoTM systems. Nature Methods 2008; an6an7.
  • 18
    Perfetto SP, Chattopadhyay PK, Lamoreaux L, Nguyen R, Ambrozak D, Koup RA, Roederer M. Amine reactive dyes: An effective tool to discriminate live and dead cells in polychromatic flow cytometry. J Immunol Methods 2006; 313: 199208.
  • 19
    Hulspas R, O'Gorman MR, Wood BL, Gratama JW, Sutherland DR. Considerations for the control of background fluorescence in clinical flow cytometry. Cytometry B Clin Cytom 2009; 76B: 355364.
  • 20
    Gross HJ, Verwer B, Houck D, Recktenwald D. Detection of rare cells at a frequency of one per million by flow cytometry. Cytometry 1993; 14: 519526.
  • 21
    Maecker HT, Trotter J. Flow cytometry controls, instrument setup, and the determination of positivity. Cytometry A 2006; 69A: 10371042.
  • 22
    Osborne MP, Wong GY, Asina S, Old LJ, Cote RJ, Rosen PP. Sensitivity of immunocytochemical detection of breast cancer cells in human bone marrow. Cancer Res 1991; 51: 27062709.